Literature DB >> 8607105

Low prevalence of the factor V Leiden mutation among "severe" hemophiliacs with a "milder" bleeding diathesis.

A A Arbini1, P M Mannucci, K A Bauer.   

Abstract

Patients with hemophilia A and B and factor levels than 1 percent of normal bleed frequently with an average number of spontaneous bleeding episodes of 20-30 or more. However there are patients with equally low levels of factor VIII or factor IX who bleed once or twice per year or not at all. To examine whether the presence of a hereditary defect predisposing to hypercoagulability might play a role in ameliorating the hemorrhagic tendency in these so-called "mild severe" hemophiliacs, we determined the prevalence of prothrombotic defects in 17 patients with hemophilia A and four patients with hemophilia B selected from 295 and 76 individuals with these disorders, respectively, followed at a large Italian hemophilia center. We tested for the presence of the Factor V Leiden mutation by PCR-amplifying a fragment of the factor V gene which contains the mutation site and then digesting the product with the restriction enzyme MnlI. None of the patients with hemophilia A and only one patient with hemophilia B was heterozygous for Factor V Leiden. None of the 21 patients had hereditary deficiencies of antithrombin III, protein C, or protein S. Our results indicate that the milder bleeding diathesis that is occasionally seen among Italian hemophiliacs with factor levels that are less than 1 percent cannot be explained by the concomitant expression of a known prothrombotic defect.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8607105

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

Review 1.  The hemostatic balance revisited through the lessons of mankind evolution.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Intern Emerg Med       Date:  2008-02-19       Impact factor: 3.397

2.  Impact of Prothrombotic Risk Factors in a Cohort of Egyptian Hemophilia A Patients.

Authors:  Mona Salah El-Din Hamdy; Aml Soliman Nasr; Manal Mohamed Makhlouf; Zainab Ali El-Saadany; Magy Samir; Dalia Saber Morgan
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

3.  Symptomatic combined homozygous factor XII deficiency and heterozygous factor V Leiden. luscaber@tin.it.

Authors:  A Girolami; P Simioni; L Scarano; B Girolami; P Zerbinati
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

Review 4.  Novel treatments for hemophilia through rebalancing of the coagulation cascade.

Authors:  Yakun Zhao; Angela C Weyand; Jordan A Shavit
Journal:  Pediatr Blood Cancer       Date:  2021-02-12       Impact factor: 3.167

Review 5.  Hemophilia A and B: molecular and clinical similarities and differences.

Authors:  Giancarlo Castaman; Davide Matino
Journal:  Haematologica       Date:  2019-08-08       Impact factor: 9.941

6.  Attenuation of phenotypical expression of severe hemophilia A in presence of simultaneous prothrombotic Factor V mutation: The debate continues.

Authors:  Saugata Acharyya; Kakoli Acharyya; Archana Parasar; Shanto Pramanik
Journal:  J Family Med Prim Care       Date:  2019-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.